ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
iVexSol, a contract development and manufacturing organization (CDMO) that produces lentiviral vectors (LVVs), has raised $23.8 million in series A-3 financing. New investors Bristol Myers Squibb, Asahi Kasei Medical, and Charles River Laboratories joined existing investors to bring the total in series A fundng to over $39 million, according to the company. iVexSol says it will use the money to invest in its intelligent vector solutions by advancing technologies, growing technical teams, and building on current infrastructure “to support the production of stable LVV producer cell lines.”
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X